Infectious Disease Therapeutics Market

According to Stratistics MRC, the Global Infectious Disease Therapeutics Market is accounted for $135.25 billion in 2025 and is expected to reach $206.49 billion by 2032 growing at a CAGR of 6.23% during the forecast period. Infectious disease therapeutics encompasses a broad range of treatments aimed at combating infections caused by bacteria, viruses, fungi, and parasites. Antibiotics, antivirals, antifungals, and antiparasitic medications are examples of these therapeutics; they all work against particular pathogens to eradicate or stop the spread of infection. The creation of innovative treatments and vaccines has become more and more important as drug-resistant bacteria and infectious diseases have increased. More accurate, efficient, and individualized treatments are now possible owing to developments in biotechnology and molecular diagnostics. 

According to the World Health Organization, viral hepatitis?(B and C) caused 1.3?million deaths in 2022, surpassing tuberculosis, and is projected to exceed the combined annual fatalities of malaria, TB, and AIDS by 2040—a stark indicator of the urgent need for potent infectious disease therapeutics.

Market Dynamics:

Driver: 

Increasing infectious disease incidence

One of the biggest health burdens in the world is still the prevalence of infectious diseases. WHO estimates that HIV/AIDS, hepatitis, malaria, and tuberculosis together account for millions of deaths each year, particularly in low- and middle-income nations. Healthcare systems are also still under stress from outbreaks like COVID-19 and seasonal illnesses like influenza. Additionally, the need for efficient treatments to lower mortality and enhance patient outcomes is sustained by this ongoing and increasing burden.

Restraint:

Expensive clinical trials and drug development

Preclinical research, several stages of clinical trials, and intensive R&D are all necessary to develop new treatments for infectious diseases, and they are all costly and time-consuming. To get a single drug to market, it can take more than ten years and cost billions of dollars. Pharmaceutical companies are discouraged from pursuing new treatments for infectious diseases that primarily affect low-income populations because the return on investment may be low. Furthermore, raising development costs and timelines are regulatory bodies' strict safety and efficacy requirements.

Opportunity:

Increasing spending on biodefense and pandemic preparedness

Governments and international organizations are investing more in health security, with a particular emphasis on developing rapid-response platforms for emerging infectious threats, improving R&D capabilities, and accumulating antivirals. Moreover, drug developers can find substantial funding and collaboration opportunities through programs like WHO's R&D Blueprint, BARDA (Biomedical Advanced Research and Development Authority), and CEPI (Coalition for Epidemic Preparedness Innovations).

Threat:

Rapid pathogen evolution and mutation

Due to their high degree of adaptability and rapid mutation, bacteria and viruses can occasionally make current treatments ineffective. The appearance of novel COVID-19 variations, like Omicron, showed how quickly pathogens can change and surpass the development of vaccines and treatments. Additionally, long-term therapeutic efficacy is threatened by this unpredictability, necessitating ongoing monitoring, reinvestment, and treatment protocol updates, which raises development risks and costs for pharmaceutical companies.

Covid-19 Impact: 

The COVID-19 pandemic changed the priorities of global health, boosted funding, and accelerated innovation, all of which had a substantial impact on the infectious disease therapeutics market. It highlighted the urgent need for quick therapeutic development, which resulted in previously unheard-of investments in mRNA technology, monoclonal antibodies, and antiviral medications. Faster treatment deployment was made possible by regulatory bodies' adoption of expedited approval pathways, which established a new standard for future drug development. The pandemic also increased the role of telemedicine and digital health in disease management, promoted cross-border cooperation, and raised public awareness of infectious diseases.

The vaccines segment is expected to be the largest during the forecast period

The vaccines segment is expected to account for the largest market share during the forecast period. Increased global awareness, extensive government support for vaccination campaigns, and extensive immunization programs are the main causes of this dominance. Vaccines are now a strategic tool for managing pandemics and epidemics in addition to providing preventive protection. Their widespread application in both adult and pediatric populations, combined with ongoing developments in mRNA and recombinant technologies, has strengthened their position as market leaders and guaranteed steady growth in both developed and emerging nations.

The intranasal segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the intranasal segment is predicted to witness the highest growth rate. This expansion is fueled by a growing desire, particularly among young and elderly populations, for needle-free, non-invasive drug delivery techniques that improve patient compliance. Moreover, intranasal formulations are perfect for emergency treatments and vaccinations because they provide a quick onset of action by avoiding the gastrointestinal tract and first-pass metabolism. Recent advancements in antiviral sprays and intranasal vaccines, increased interest in and investment in this market segment and established it as a crucial area for future growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, propelled by its sophisticated healthcare system, substantial healthcare expenditures, and robust presence of top biotechnology and pharmaceutical firms. The area gains from strong R&D capacities, broad use of cutting-edge treatment alternatives, and encouraging regulatory environments such as the FDA's expedited approval processes. Additionally, the high incidence of infectious diseases like hepatitis, HIV, and influenza, as well as government-sponsored immunization campaigns and public health campaigns, also play a big role in market dominance.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Rising infectious disease rates, growing healthcare infrastructure, and rising public and private investments in drug development and medical research are the main drivers of this growth. Because of their expanding populations and increased awareness of disease, countries like China, India, and Southeast Asia are seeking more affordable and efficient treatments. Furthermore, the launch of regional biotech companies, advancements in diagnostic technology and government-led vaccination campaigns are speeding up the adoption of treatments. The rapidly expanding market is further supported by the region's changing regulatory environment.

Key players in the market

Some of the key players in Infectious Disease Therapeutics Market include BioCryst Pharmaceuticals Inc. , GlaxoSmithKline plc, AbbVie Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, Gilead Sciences Inc., AstraZeneca Inc, Merck & Co., Inc. , Bayer AG, Amgen Inc., Novartis AG, Bristol-Myers Squibb (BMS), Abbott Laboratories, Pfizer Inc. , Sanofi , Janssen Pharmaceutical Inc., Takeda Pharmaceutical and Sandoz International GmbH.

Key Developments:

In June 2025, BioCryst Pharmaceuticals, Inc. announced the extension of its consulting agreement with former Chief Financial Officer Anthony Doyle. This information was disclosed in a recent SEC filing. The company, with a market capitalization of $2.34 billion, has shown impressive momentum with a 66% return over the past year and revenue of $503 million in the last twelve months.

In February 2025, AbbVie and Xilio Therapeutics, Inc. announced collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's proprietary technology. Xilio has developed a proprietary, clinically-validated platform technology for tumor-activated biologics.

In January 2025, GSK plc has agreed to acquire IDRx, a Boston-based, clinical-stage Biopharmaceutical Company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.

Infection Types Covered:
• Bacterial Infections
• Viral Infections
• Fungal Infections
• Parasitic Infections
• Other Infection Types

Drug Classes Covered:
• Antibacterials
• Antivirals
• Antifungals
• Antiparasitic Drugs
• Vaccines
• Other Drug Classes

Mode of Administrations Covered:
• Oral
• Parenteral
• Intranasal

Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels

End Users Covered:
• Hospitals & Clinics
• Research Organizations
• Diagnostic Centres
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances